Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Minneapolis, Minnesota 55415


The purpose of this study is to examine the effects of HIV treatment (antiretroviral therapy) and aspirin use on risk for cardiovascular disease among HIV infected persons.

Study summary:

Cardiovascular disease is now a major health concern among persons with HIV infection. Our general hypothesis is that HIV-mediated inflammation and injury to vascular surfaces up-regulates thrombotic pathways and leads to damage of blood vessels that is promotes development of cardiovascular disease. HIV drug treatment (antiretroviral therapy; ART) may reduce inflammation and vessel injury via suppression of HIV replication, but also includes side effects or toxicity that may increase risk for cardiovascular disease in and of itself. In this context, additional anti-inflammatory and anti-thrombotic medications are needed. Acetylsalicylic acid (aspirin) is an excellent candidate and is commonly used for secondary prevention of cardiovascular events in the general population, but few studies have examined it's use in persons with HIV infection. The goal of this study is to generate pilot data regarding changes in measures of cardiovascular risk, as determined by reductions in inflammatory and thrombotic blood markers and a decrease in blood vessel injury (blood markers) and dysfunction (assessment of arterial elasticity), that occur after starting ART and aspirin among persons with HIV infection.


Inclusion Criteria: 1. HIV-infected (by positive HIV Ab or detectable HIV RNA level) 2. No ART for at least previous 3 months 3. Ready to start or re-start ART (regimen pre-chosen by patient and provider) Exclusion Criteria: 1. Age < 18 years, or >60 years 2. Pregnancy 3. Current aspirin use 4. Presence of known atherosclerotic CVD determined by: 1. Previous myocardial infarction 2. Significant coronary atherosclerosis by angiography 3. Coronary revascularization procedure (coronary stent or surgical bypass) 4. Previous cerebral vascular accident (stroke) 5. Ischemic cardiomyopathy 6. Carotid stenosis (>25% narrowing by carotid ultrasound) 7. Aortic aneurysm 8. Symptomatic peripheral vascular disease (claudication) 9. Surgical revascularization procedure of peripheral vessels 5. Hospitalization (within prior 2 weeks of study entry) 6. Concurrent self-limited bacterial infections (does not include chronic viral infections) 7. Clinical or pathologic diagnosis of systemic vasculitis 8. Active drug or alcohol use



Primary Contact:

Principal Investigator
Jason V Baker, MD, MS
University of Minnesota; HCMC

Backup Contact:


Location Contact:

Minneapolis, Minnesota 55415
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.